Autolus Therapeutics raised $100.8 million

Days after announcing the first response rates from a Phase I/II trial of CAR T cell therapy AUTO1, Autolus raised $100.8 million in a follow-on offering.

  • 11 April 2019

On April 1, 2019,  Autolus, a company in which Cancer Research UK has an equity position, said that after one month, CD19-targeting AUTO1 led to molecular complete responses in eight of nine evaluable patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL). At five months, six of 10 were alive and in molecular remission. There were no cases of grade 3 or higher cytokine release syndrome.

Notes to Editors

Autolus Therapeutics is a spin out of UCL Business which incorporated Cancer Research UK licensed IP at formation.

Read more here.

Related content

Scientist wearing a white lab coat and goggle looking at some equipment.

Drug discovery and development

We identify, develop and commercialise promising ideas into successful cancer therapeutics, diagnostics and enabling technologies.